Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
7°
Sunny
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
92.58
+0.17 (+0.18%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
52
53
Next >
A Bullish Sign Appears On Gilead Sciences's Chart
October 05, 2022
If history is any guide, there may be good fortune ahead for shares of Gilead Sciences (NASDAQ:GILD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for...
Via
Benzinga
What Are Whales Doing With Gilead Sciences
October 04, 2022
A whale with a lot of money to spend has taken a noticeably bullish stance on Gilead Sciences. Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 17 strange trades.
Via
Benzinga
Why This Gilead Analyst Believes The Stock Is Highly Undervalued
October 04, 2022
While there is increased visibility for Gilead Sciences, Inc’s (NASDAQ: GILD) HIV franchise, its emerging oncology franchise is not well reflected in its valuation, according to JPMorgan.
Via
Benzinga
Expert Ratings for Gilead Sciences
October 04, 2022
Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
October 03, 2022
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.
Via
Talk Markets
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
October 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
WHO Recommends Gilead's COVID-19 Therapy For Severe Disease
September 16, 2022
Via
Benzinga
Why Is Gilead Sciences (GILD) Stock Up Today?
September 12, 2022
Gilead Sciences has a low valuation, but no growth. Perhaps settling a patent lawsuit will help give GILD stock the boost it needs.
Via
InvestorPlace
3 Biotech Stocks to Sell in October
September 29, 2022
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.
Via
InvestorPlace
Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29
September 29, 2022
Reuters
Via
Benzinga
Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
September 29, 2022
U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences...
Via
Benzinga
7 Monthly Dividend Stocks to Buy for Safety
September 29, 2022
These safe monthly dividend stocks offer investors incredible dividend yields and healthy upside potential
Via
InvestorPlace
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
September 27, 2022
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market.
Via
InvestorPlace
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
September 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Completes Acquisition of MiroBio
September 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
September 20, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.63% on an annualized basis producing an average annual return of 7.98%. Currently, Gilead Sciences has a market...
Via
Benzinga
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
September 20, 2022
Via
Benzinga
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
September 19, 2022
As cases of the monkeypox virus continue to grow, the race is on for a way to fight this once-rare disease. Since the first reports of monkeypox infection in the United States started popping up in...
Via
Benzinga
7 Penny Stocks That Actually Have a Buy Rating
September 19, 2022
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now.
Via
InvestorPlace
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
September 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
September 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says
September 15, 2022
Gilead Sciences Inc (NASDAQ: GILD) disclosed agreements with generic manufacturers that delay the U.S. launch of generic TAF products from 2025 to 2031/2032.
Via
Benzinga
Taking Charge of Your Care This Blood Cancer Awareness Month
September 15, 2022
(BPT) - Being empowered often comes from being informed. And when it comes to diseases like blood cancer, having or not having information can make a significant difference in outcomes.
Via
Brandpoint
Topics
Death
Exposures
Death
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
September 14, 2022
Via
Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
September 13, 2022
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it." The...
Via
Benzinga
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
September 13, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Why HIV Testing Should Be an Important and Normal Part of Your Self-Care Routine
September 09, 2022
(BPT) - The COVID-19 pandemic introduced unprecedented challenges and altered ways of living across the globe. Now, more than two years later, the effects are still felt widely. Many non-emergent...
Via
Brandpoint
Exposures
COVID-19
Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
September 08, 2022
Making its debut on 05/08/2007, smart beta exchange traded fund First Trust Large Cap Core AlphaDEX ETF (ETF:FEX) provides investors broad exposure to the Style Box - Large Cap Blend category of the...
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.